These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 23172750)

  • 1. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.
    Smolen JS; Schoels MM; Nishimoto N; Breedveld FC; Burmester GR; Dougados M; Emery P; Ferraccioli G; Gabay C; Gibofsky A; Gomez-Reino JJ; Jones G; Kvien TK; Murakami M; Betteridge N; Bingham CO; Bykerk V; Choy EH; Combe B; Cutolo M; Graninger W; Lanas A; Martin-Mola E; Montecucco C; Ostergaard M; Pavelka K; Rubbert-Roth A; Sattar N; Scholte-Voshaar M; Tanaka Y; Trauner M; Valentini G; Winthrop KL; de Wit M; van der Heijde D
    Ann Rheum Dis; 2013 Apr; 72(4):482-92. PubMed ID: 23172750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
    Aletaha D; Kerschbaumer A; Kastrati K; Dejaco C; Dougados M; McInnes IB; Sattar N; Stamm TA; Takeuchi T; Trauner M; van der Heijde D; Voshaar M; Winthrop KL; Ravelli A; Betteridge N; Burmester GR; Bijlsma JW; Bykerk V; Caporali R; Choy EH; Codreanu C; Combe B; Crow MK; de Wit M; Emery P; Fleischmann RM; Gabay C; Hetland ML; Hyrich KL; Iagnocco A; Isaacs JD; Kremer JM; Mariette X; Merkel PA; Mysler EF; Nash P; Nurmohamed MT; Pavelka K; Poor G; Rubbert-Roth A; Schulze-Koops H; Strangfeld A; Tanaka Y; Smolen JS
    Ann Rheum Dis; 2023 Jun; 82(6):773-787. PubMed ID: 35953263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    McLaughlin M; Östör A
    Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
    Song SN; Yoshizaki K
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab in the treatment of rheumatoid arthritis and beyond.
    Shetty A; Hanson R; Korsten P; Shawagfeh M; Arami S; Volkov S; Vila O; Swedler W; Shunaigat AN; Smadi S; Sawaqed R; Perkins D; Shahrara S; Sweiss NJ
    Drug Des Devel Ther; 2014; 8():349-64. PubMed ID: 24729685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.
    Mitchell E; Jones G
    Expert Rev Clin Immunol; 2016; 12(2):103-14. PubMed ID: 26629984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.
    Schoels MM; van der Heijde D; Breedveld FC; Burmester GR; Dougados M; Emery P; Ferraccioli G; Gabay C; Gibofsky A; Gomez-Reino JJ; Jones G; Kvien TK; Murakami M; Nishimoto N; Smolen JS
    Ann Rheum Dis; 2013 Apr; 72(4):583-9. PubMed ID: 23144446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tocilizumab in rheumatoid arthritis].
    Rueda Gotor J; Blanco Alonso R
    Reumatol Clin; 2011 Mar; 6S3():S29-32. PubMed ID: 21794769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis.
    Ogata A; Kato Y; Higa S; Maeda K
    Expert Opin Drug Deliv; 2019 Jun; 16(6):639-648. PubMed ID: 31088167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.
    Woodrick RS; Ruderman EM
    Bull NYU Hosp Jt Dis; 2012; 70(3):195-9. PubMed ID: 23259628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
    Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab (Actemra).
    Sheppard M; Laskou F; Stapleton PP; Hadavi S; Dasgupta B
    Hum Vaccin Immunother; 2017 Sep; 13(9):1972-1988. PubMed ID: 28841363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
    Avci AB; Feist E; Burmester GR
    BioDrugs; 2018 Dec; 32(6):531-546. PubMed ID: 30488231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study.
    Nakagawa J; Koyama Y; Kawakami A; Ueki Y; Tsukamoto H; Horiuchi T; Nagano S; Uchino A; Ota T; Akahoshi M; Akashi K
    Arthritis Res Ther; 2017 Aug; 19(1):185. PubMed ID: 28800780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis.
    June RR; Olsen NJ
    Expert Opin Biol Ther; 2016 Oct; 16(10):1303-9. PubMed ID: 27464017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection.
    Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2019; 13():57-70. PubMed ID: 30587928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting interleukin-6 in rheumatoid arthritis.
    Md Yusof MY; Emery P
    Drugs; 2013 Mar; 73(4):341-56. PubMed ID: 23456676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous Tocilizumab Is Effective for Treatment of Elderly-Onset Rheumatoid Arthritis.
    Kondo N; Fujisawa J; Endo N
    Tohoku J Exp Med; 2020 May; 251(1):9-18. PubMed ID: 32404541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of IL-6 blockade tocilizumab and TNF inhibitors on angiogenesis in synovial tissues from patients with rheumatoid arthritis.
    Hirohata S; Abe A; Murasawa A; Kanamono T; Tomita T; Yoshikawa H
    Mod Rheumatol; 2017 Sep; 27(5):766-772. PubMed ID: 27846751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.